Anti-tumor effects of inactivated Sendai virus particles with an IL-2 gene on angiosarcoma

Clinical Immunology

Volumn 149, Issue 1, 2013, Pages 1-10

  Takehara, Yuki ^a   Satoh, Takahiro ^b   Nishizawa, Aya ^a   Saeki, Kazumi ^a   Nakamura, Masataka ^a   Masuzawa, Mikio ^c   Kaneda, Yasufumi ^d   Katayama, Ichiro ^d   Yokozeki, Hiroo ^a  

^a TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^c KITASATO UNIVERSITY   (Japan)

^d OSAKA UNIVERSITY   (Japan)

Author keywords

ISOS 1 cells; Myeloid derived suppressor cells; Sunitinib

Indexed keywords

HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; INTERLEUKIN 2; SUNITINIB; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELLS; CONTROLLED STUDY; MOUSE; NATURAL KILLER CELL; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SENDAI VIRUS; SUPPRESSOR CELL; T LYMPHOCYTE; VIRUS ENVELOPE;

BMDC; BONE MARROW-DERIVED DENDRITIC CELLS; DCS; DENDRITIC CELLS; HEMAGGLUTINATING VIRUS OF JAPAN ENVELOPE; HVJ-E; HVJ-E CARRYING IL-2 GENE; HVJ-E CARRYING PVAX1 PLASMID; HVJ-E/IL-2; HVJ-E/PVAX1; ISOS-1 CELLS; ISOS-1 CELLS FUSED WITH HVJ-E; ISOS-1/HVJ; MDSC; MYELOID-DERIVED SUPPRESSOR CELLS; REGULATORY T CELLS; S.D; STANDARD DEVIATIONS; SUNITINIB; TILS; TREGS; TUMOR INFILTRATING LYMPHOCYTES;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL PROLIFERATION; DENDRITIC CELLS; FEMALE; HEMANGIOSARCOMA; INDOLES; INTERFERON-GAMMA; INTERLEUKIN-2; LYMPHOCYTES; MICE; MICE, INBRED BALB C; ONCOLYTIC VIROTHERAPY; PROTEIN KINASE INHIBITORS; PYRROLES; SENDAI VIRUS; SKIN NEOPLASMS; TUMOR BURDEN; VIRION;

EID: 84880619769     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2013.05.019     Document Type: Article

References (33)

1. Donghi D., Dummer R., Cozzio A. Complete remission in a patient with multifocal metastatic cutaneous angiosarcoma with a combination of paclitaxel and sorafenib. Br. J. Dermatol. 2010, 162:697-699.
2. Hirata T., Yonemori K., Ando M., Hirakawa A., Tsuda H., Hasegawa T., Chuman H., Namikawa K., Yamazaki N., Fujiwara Y. Efficacy of taxane regimens in patients with metastatic angiosarcoma. Eur. J. Dermatol. 2011, 21:539-545.
3. Italiano A., Cioffi A., Penel N., Levra M.G., Delcambre C., Kalbacher E., Chevreau C., Bertucci F., Isambert N., Blay J.Y., Bui B., Antonescu C., D'Adamo D.R., Maki R.G., Keohan M.L. Comparison of doxorubicin and weekly paclitaxel efficacy in metastatic angiosarcomas. Cancer 2012, 118:3330-3336.
4. Kaneda Y. A non-replicating oncolytic vector as a novel therapeutic tool against cancer. BMB Rep. 2010, 43:773-780.
5. Kurooka M., Kaneda Y. Inactivated Sendai virus particles eradicate tumors by inducing immune responses through blocking regulatory T cells. Cancer Res. 2007, 67:227-236.
6. Fujihara A., Kurooka M., Miki T., Kaneda Y. Intratumoral injection of inactivated Sendai virus particles elicits strong antitumor activity by enhancing local CXCL10 expression and systemic NK cell activation. Cancer Immunol. Immunother. 2008, 57:73-84.
7. Rosenberg S.A., Yang J.C., Topalian S.L., Schwartzentruber D.J., Weber J.S., Parkinson D.R., Seipp C.A., Einhorn J.H., White D.E. Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. J. Am. Med. Assoc. 1994, 271:907-913.
8. Ihda H., Tokura Y., Fushimi M., Yokote R., Hashizume H., Shirahama S., Iwatsuki K., Murakami K., Takigawa M. Malignant hemangioendothelioma. Int. J. Dermatol. 1995, 34:811-816.
9. Masuzawa M., Higashi K., Nishioka K., Nishiyama S. Successful immunotherapy of malignant hemangioendothelioma using recombinant interleukin-2 Nihon Hifuka Gakkai zasshi. Jpn. J. Dermatol. 1988, 98:367-369.
10. Chavez A.R., Buchser W., Basse P.H., Liang X., Appleman L.J., Maranchie J.K., Zeh H., de Vera M.E., Lotze M.T. Pharmacologic administration of interleukin-2. Ann. N. Y. Acad. Sci. 2009, 1182:14-27.
11. Dutcher J.P., Gaynor E.R., Boldt D.H., Doroshow J.H., Bar M.H., Sznol M., Mier J., Sparano J., Fisher R.I., Weiss G., et al. A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 1991, 9:641-648.
12. Kruit W.H., Punt C.J., Goey S.H., de Mulder P.H., Gratama J.W., Eggermont A.M., Bolhuis R.L., Stoter G. Dose efficacy study of two schedules of high-dose bolus administration of interleukin 2 and interferon alpha in metastatic melanoma. Br. J. Cancer 1996, 74:951-955.
13. Chow L.Q., Eckhardt S.G. Sunitinib: from rational design to clinical efficacy. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2007, 25:884-896.
14. Motzer R.J., Michaelson M.D., Redman B.G., Hudes G.R., Wilding G., Figlin R.A., Ginsberg M.S., Kim S.T., Baum C.M., DePrimo S.E., Li J.Z., Bello C.L., Theuer C.P., George D.J., Rini B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2006, 24:16-24.
15. Masuzawa M., Fujimura T., Tsubokawa M., Nishiyama S., Katsuoka K., Terada E., Kunita S., Sakurai Y., Kato H. Establishment of a new murine-phenotypic angiosarcoma cell line (ISOS-1). J. Dermatol. Sci. 1998, 16:91-98.
16. Matsuda M., Nimura K., Shimbo T., Hamasaki T., Yamamoto T., Matsumura A., Kaneda Y. Immunogene therapy using immunomodulating HVJ-E vector augments anti-tumor effects in murine malignant glioma. J. Neurooncol. 2011, 103:19-31.
17. Fujihashi K., Taguchi T., McGhee J.R., Eldridge J.H., Bruce M.G., Green D.R., Singh B., Kiyono H. Regulatory function for murine intraepithelial lymphocytes. Two subsets of CD3+, T cell receptor-1+ intraepithelial lymphocyte T cells abrogate oral tolerance. J. Immunol. 1990, 145:2010-2019.
18. Lecoeur H., Fevrier M., Garcia S., Riviere Y., Gougeon M.L. A novel flow cytometric assay for quantitation and multiparametric characterization of cell-mediated cytotoxicity. J. Immunol. Methods 2001, 253:177-187.
19. Lutz M.B., Kukutsch N., Ogilvie A.L., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse bone marrow. J. Immunol. Methods 1999, 223:77-92.
20. Kawaguchi Y., Miyamoto Y., Inoue T., Kaneda Y. Efficient eradication of hormone-resistant human prostate cancers by inactivated Sendai virus particle. Int. J. Cancer 2009, 124:2478-2487.
21. Gabrilovich D.I., Bronte V., Chen S.H., Colombo M.P., Ochoa A., Ostrand-Rosenberg S., Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res. 2007, 67:425. (author reply 426).
22. Kao J., Ko E.C., Eisenstein S., Sikora A.G., Fu S., Chen S.H. Targeting immune suppressing myeloid-derived suppressor cells in oncology. Crit. Rev. Oncol. Hematol. 2011, 77:12-19.
23. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., Divino C.M., Chen S.H. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 2006, 66:1123-1131.
24. Gabrilovich D.I., Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 2009, 9:162-174.
25. Kawano H., Komaba S., Yamasaki T., Maeda M., Kimura Y., Maeda A., Kaneda Y. New potential therapy for orthotopic bladder carcinoma by combining HVJ envelope with doxorubicin. Cancer Chemother. Pharmacol. 2008, 61:973-978.
26. Schueneman A.J., Himmelfarb E., Geng L., Tan J., Donnelly E., Mendel D., McMahon G., Hallahan D.E. SU11248 maintenance therapy prevents tumor regrowth after fractionated irradiation of murine tumor models. Cancer Res. 2003, 63:4009-4016.
27. Bose A., Taylor J.L., Alber S., Watkins S.C., Garcia J.A., Rini B.I., Ko J.S., Cohen P.A., Finke J.H., Storkus W.J. Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. Int. J. Cancer 2011, 129:2158-2170.
28. Xin H., Zhang C., Herrmann A., Du Y., Figlin R., Yu H. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells. Cancer Res. 2009, 69:2506-2513.
29. Iwadate Y., Inoue M., Saegusa T., Tokusumi Y., Kinoh H., Hasegawa M., Tagawa M., Yamaura A., Shimada H. Recombinant Sendai virus vector induces complete remission of established brain tumors through efficient interleukin-2 gene transfer in vaccinated rats. Clin. Cancer Res. 2005, 11:3821-3827.
30. Shojaei F., Wu X., Malik A.K., Zhong C., Baldwin M.E., Schanz S., Fuh G., Gerber H.P., Ferrara N. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
31. Gabitass R.F., Annels N.E., Stocken D.D., Pandha H.A., Middleton G.W. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol. Immunother. CII 2011, 60:1419-1430.
32. Nonaka K., Saio M., Suwa T., Frey A.B., Umemura N., Imai H., Ouyang G.F., Osada S., Balazs M., Adany R., Kawaguchi Y., Yoshida K., Takami T. Skewing the Th cell phenotype toward Th1 alters the maturation of tumor-infiltrating mononuclear phagocytes. J. Leukoc. Biol. 2008, 84:679-688.
33. Thakur A., Schalk D., Sarkar S.H., Al-Khadimi Z., Sarkar F.H., Lum L.G. A Th1 cytokine-enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells. Cancer Immunol. Immunother. CII 2012, 61:497-509.